Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.

Mannose-binding lectin (MBL) is a key soluble effector of the innate immune system that recognizes pathogen-specific surface glycans. Surprisingly, low-producing MBL genetic variants that may predispose children and immunocompromised individuals to infectious diseases are more common than would be e...

Full description

Bibliographic Details
Main Authors: Matthew Brudner, Marshall Karpel, Calli Lear, Li Chen, L Michael Yantosca, Corinne Scully, Ashish Sarraju, Anna Sokolovska, M Reza Zariffard, Damon P Eisen, Bruce A Mungall, Darrell N Kotton, Amel Omari, I-Chueh Huang, Michael Farzan, Kazue Takahashi, Lynda Stuart, Gregory L Stahl, Alan B Ezekowitz, Gregory T Spear, Gene G Olinger, Emmett V Schmidt, Ian C Michelow
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3614905?pdf=render
id doaj-bf6071a8ac8d442080d3e3d14a86b618
record_format Article
spelling doaj-bf6071a8ac8d442080d3e3d14a86b6182020-11-24T20:50:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6083810.1371/journal.pone.0060838Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.Matthew BrudnerMarshall KarpelCalli LearLi ChenL Michael YantoscaCorinne ScullyAshish SarrajuAnna SokolovskaM Reza ZariffardDamon P EisenBruce A MungallDarrell N KottonAmel OmariI-Chueh HuangMichael FarzanKazue TakahashiLynda StuartGregory L StahlAlan B EzekowitzGregory T SpearGene G OlingerEmmett V SchmidtIan C MichelowMannose-binding lectin (MBL) is a key soluble effector of the innate immune system that recognizes pathogen-specific surface glycans. Surprisingly, low-producing MBL genetic variants that may predispose children and immunocompromised individuals to infectious diseases are more common than would be expected in human populations. Since certain immune defense molecules, such as immunoglobulins, can be exploited by invasive pathogens, we hypothesized that MBL might also enhance infections in some circumstances. Consequently, the low and intermediate MBL levels commonly found in human populations might be the result of balancing selection. Using model infection systems with pseudotyped and authentic glycosylated viruses, we demonstrated that MBL indeed enhances infection of Ebola, Hendra, Nipah and West Nile viruses in low complement conditions. Mechanistic studies with Ebola virus (EBOV) glycoprotein pseudotyped lentiviruses confirmed that MBL binds to N-linked glycan epitopes on viral surfaces in a specific manner via the MBL carbohydrate recognition domain, which is necessary for enhanced infection. MBL mediates lipid-raft-dependent macropinocytosis of EBOV via a pathway that appears to require less actin or early endosomal processing compared with the filovirus canonical endocytic pathway. Using a validated RNA interference screen, we identified C1QBP (gC1qR) as a candidate surface receptor that mediates MBL-dependent enhancement of EBOV infection. We also identified dectin-2 (CLEC6A) as a potentially novel candidate attachment factor for EBOV. Our findings support the concept of an innate immune haplotype that represents critical interactions between MBL and complement component C4 genes and that may modify susceptibility or resistance to certain glycosylated pathogens. Therefore, higher levels of native or exogenous MBL could be deleterious in the setting of relative hypocomplementemia which can occur genetically or because of immunodepletion during active infections. Our findings confirm our hypothesis that the pressure of infectious diseases may have contributed in part to evolutionary selection of MBL mutant haplotypes.http://europepmc.org/articles/PMC3614905?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Matthew Brudner
Marshall Karpel
Calli Lear
Li Chen
L Michael Yantosca
Corinne Scully
Ashish Sarraju
Anna Sokolovska
M Reza Zariffard
Damon P Eisen
Bruce A Mungall
Darrell N Kotton
Amel Omari
I-Chueh Huang
Michael Farzan
Kazue Takahashi
Lynda Stuart
Gregory L Stahl
Alan B Ezekowitz
Gregory T Spear
Gene G Olinger
Emmett V Schmidt
Ian C Michelow
spellingShingle Matthew Brudner
Marshall Karpel
Calli Lear
Li Chen
L Michael Yantosca
Corinne Scully
Ashish Sarraju
Anna Sokolovska
M Reza Zariffard
Damon P Eisen
Bruce A Mungall
Darrell N Kotton
Amel Omari
I-Chueh Huang
Michael Farzan
Kazue Takahashi
Lynda Stuart
Gregory L Stahl
Alan B Ezekowitz
Gregory T Spear
Gene G Olinger
Emmett V Schmidt
Ian C Michelow
Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
PLoS ONE
author_facet Matthew Brudner
Marshall Karpel
Calli Lear
Li Chen
L Michael Yantosca
Corinne Scully
Ashish Sarraju
Anna Sokolovska
M Reza Zariffard
Damon P Eisen
Bruce A Mungall
Darrell N Kotton
Amel Omari
I-Chueh Huang
Michael Farzan
Kazue Takahashi
Lynda Stuart
Gregory L Stahl
Alan B Ezekowitz
Gregory T Spear
Gene G Olinger
Emmett V Schmidt
Ian C Michelow
author_sort Matthew Brudner
title Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
title_short Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
title_full Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
title_fullStr Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
title_full_unstemmed Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
title_sort lectin-dependent enhancement of ebola virus infection via soluble and transmembrane c-type lectin receptors.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Mannose-binding lectin (MBL) is a key soluble effector of the innate immune system that recognizes pathogen-specific surface glycans. Surprisingly, low-producing MBL genetic variants that may predispose children and immunocompromised individuals to infectious diseases are more common than would be expected in human populations. Since certain immune defense molecules, such as immunoglobulins, can be exploited by invasive pathogens, we hypothesized that MBL might also enhance infections in some circumstances. Consequently, the low and intermediate MBL levels commonly found in human populations might be the result of balancing selection. Using model infection systems with pseudotyped and authentic glycosylated viruses, we demonstrated that MBL indeed enhances infection of Ebola, Hendra, Nipah and West Nile viruses in low complement conditions. Mechanistic studies with Ebola virus (EBOV) glycoprotein pseudotyped lentiviruses confirmed that MBL binds to N-linked glycan epitopes on viral surfaces in a specific manner via the MBL carbohydrate recognition domain, which is necessary for enhanced infection. MBL mediates lipid-raft-dependent macropinocytosis of EBOV via a pathway that appears to require less actin or early endosomal processing compared with the filovirus canonical endocytic pathway. Using a validated RNA interference screen, we identified C1QBP (gC1qR) as a candidate surface receptor that mediates MBL-dependent enhancement of EBOV infection. We also identified dectin-2 (CLEC6A) as a potentially novel candidate attachment factor for EBOV. Our findings support the concept of an innate immune haplotype that represents critical interactions between MBL and complement component C4 genes and that may modify susceptibility or resistance to certain glycosylated pathogens. Therefore, higher levels of native or exogenous MBL could be deleterious in the setting of relative hypocomplementemia which can occur genetically or because of immunodepletion during active infections. Our findings confirm our hypothesis that the pressure of infectious diseases may have contributed in part to evolutionary selection of MBL mutant haplotypes.
url http://europepmc.org/articles/PMC3614905?pdf=render
work_keys_str_mv AT matthewbrudner lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT marshallkarpel lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT callilear lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT lichen lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT lmichaelyantosca lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT corinnescully lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT ashishsarraju lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT annasokolovska lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT mrezazariffard lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT damonpeisen lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT bruceamungall lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT darrellnkotton lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT amelomari lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT ichuehhuang lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT michaelfarzan lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT kazuetakahashi lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT lyndastuart lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT gregorylstahl lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT alanbezekowitz lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT gregorytspear lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT genegolinger lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT emmettvschmidt lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
AT iancmichelow lectindependentenhancementofebolavirusinfectionviasolubleandtransmembranectypelectinreceptors
_version_ 1716804549594841088